CJC-1295 DAC (Drug Affinity Complex), also known as CJC-1295, is a synthetic GHRH (Growth Hormone Releasing Hormone) that is long acting. After administration, it covalently binds to albumin naturally created by the human body, causing it to extend its duration of action. This means it has a far longer half life (between six and eight days) than other peptides like Sermorelin and Mod GRF 1-29 . Sermorelin and Modified GRF 1-29 have a half life of 5-10 minutes , and about 30 minutes , respectively. A shorter half life results in inefficiency because the peptide does not reach the pituitary within enough time for the peptide to become effectual. Unlike Mod GRF 1-29, CJC-1295 DAC is a drug affinity complex, where there is a lysine connection to maleimidoproprionic acid (MPA) .
In the average and healthy human body, growth hormones are kept in the pituitary gland. A GHRH, naturally occurring or synthetic, signals to the pituitary to release growth hormone. Most individuals, naturally, are able to create growth hormone in their pituitary gland. However, some can not release the necessary amount of growth hormone. GHRP increases the amount of growth hormone releasing cells. The quantity released by each cell is unaffected. CJC-1295 DAC, and other peptides like GHRP-6 and GHRP-2, have the possibility of assisting in the attainment of necessary growth hormone levels.
Clinical studies have shown that the administration of CJC-1295, which was developed by ConjuChem, in certain specific situations and intervals, may cause the achievement of normal body weight when GHRH levels are low, greater body weight, and an increase in total pituitary RNA and growth hormone. The last of which suggests that more growth hormone releasing cells were created . Other studies have provided evidence that one administration of CJC-1295 produced sustained elevations of serum growth hormone and insulin-like growth factor 1 levels in normal subjects for nearly fourteen days .